SCHEMBL6487221

SCHEMBL6487221

COc1cccc(-c2cnc(C(=O)NC3CC4CNC3C4)s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.49
HDAC1 Q13547 6/20 0.49
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
USP30 Q70CQ3 1/20 0.43
NAAA Q02083 2/20 0.40
CHEK1 O14757 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.38
FAAH O00519 1/20 0.37
IKBKB O14920 1/20 0.37
DGAT1 O75907 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495918 0.90 HDAC1 (0.46) HDAC6HDAC1USP30NAAANPC1
SCHEMBL6497171 0.87 HDAC1 (0.46) HDAC6HDAC1HSD17B1HSD17B2USP30
SCHEMBL6500752 0.87 USP30 (0.52) HDAC6HDAC1USP30DGAT1
SCHEMBL6489240 0.86 USP30 (0.43) HDAC6HDAC1USP30CHEK1DGAT1
SCHEMBL6499660 0.86 USP30 (0.43) HDAC6HDAC1HSD17B1HSD17B2USP30
SCHEMBL6497610 0.85 HDAC6 (0.47) HDAC6HDAC1USP30CHEK1NPC1
SCHEMBL6491679 0.85 USP30 (0.43) USP30CHEK1DGAT1
SCHEMBL6498904 0.85 HDAC6 (0.50) HDAC6HSD17B1HSD17B2CHEK1NPC1
SCHEMBL6490517 0.84 NQO2 (0.44) USP30CHEK1NPC1RAB9AKMT2A
SCHEMBL6487324 0.84 HDAC6 (0.52) HDAC6HDAC1HSD17B1HSD17B2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 HDAC6 1069/4885HDAC1 467/4885HSD17B1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.